Carlo Perno to Treatment Outcome
This is a "connection" page, showing publications Carlo Perno has written about Treatment Outcome.
Connection Strength
0.062
-
Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis. J Infect. 2020 10; 81(4):e11-e17.
Score: 0.008
-
Tuberculosis among asylum seekers in Milan, Italy: epidemiological analysis and evaluation of interventions. Eur Respir J. 2019 10; 54(4).
Score: 0.008
-
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. J Antimicrob Chemother. 2018 12 01; 73(12):3460-3470.
Score: 0.007
-
HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals. Infection. 2018 Oct; 46(5):717-720.
Score: 0.007
-
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. Antivir Ther. 2018; 23(3):249-257.
Score: 0.007
-
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study. J Antimicrob Chemother. 2017 Dec 01; 72(12):3420-3424.
Score: 0.007
-
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? J Hepatol. 2018 03; 68(3):597-600.
Score: 0.007
-
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS One. 2017; 12(5):e0177352.
Score: 0.006
-
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017 06; 2(6):427-434.
Score: 0.006